3YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| Thalidomide-Piperazine-PEG1-COOH | 2731007-11-5 | |
| Pomalidomide-PEG4-C-COOH | E3 Ligase Ligand-Linker Conjugates 1 | 2097938-44-6 |
| MRT00033659 | 1401731-54-1 | |
| GSK682753A | 1334294-76-6 | 1334294-76-6 |
| ML401 | 1597489-14-9 | |
| NIBR189 | 1599432-08-2 | |
| EAI045 | EAI-045 | 1942114-09-1 |
| EAI001 | 2-(1-氧代异吲哚啉-2-基)-2-苯基-N-(噻唑-2-基)乙酰胺 | 892772-75-7 |
| ARRY-380 analog | ARRY-380 | 937265-83-3 |
| TAS0728 | 2088323-16-2 | |
| Zipalertinib | 齐帕勒替尼 | 1661854-97-2 |
| Alflutinib mesylate | AST2818甲磺酸盐 | 2130958-55-1 |
| JND3229 | 2260886-64-2 | |
| Gefitinib-based PROTAC 3 | 2230821-27-7 | |
| Nazartinib | EGF816 | 1508250-71-2 |
| EGFR-IN-11 | 2463200-44-2 | |
| AZ7550 Mesylate | 2319837-99-3 | |
| CP-724714 | 2-甲氧基-N-[3-[4-[[3-甲基-4-[(6-甲基-3-吡啶基)氧基]苯基]氨基]-6-喹唑啉基]-2-丙烯-1-基]乙酰胺 | 537705-08-1 |
| BMS-690514 | (3R,4R)-4-氨基-1-[[4-[(3-甲氧基苯基)氨基]吡咯并[2,1-F][1,2,4]三嗪-5-基]甲基]哌啶-3-醇 | 859853-30-8 |
| PD153035 hydrochloride | 4-[(3-溴苯基)氨基]-6,7-二甲氧基喹啉 | 153436-54-5 |
| AG-1478 | AG1478 | 153436-53-4 |
| AST-1306 | 897383-62-9 | |
| Mutant EGFR inhibitor | N-[5-[[5-氯-4-(1H-吲哚-3-基)-2-嘧啶基]氨基]-2-[[2-(二甲基氨基)乙基]甲基氨基]-4-甲氧基苯基]-2-丙烯酰胺 | 1421373-62-7 |
| AZD-9291 (Mesylate) | AZD9291(甲磺酸盐) | 1421373-66-1 |
| Thalidomide-piperazine-Boc | 1-Piperazinecarboxylic acid, 4-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-, 1,1-dimethylethyl ester | 2222114-64-7 |
| Simotinib | 944258-89-3 | |
| Lazertinib | 拉泽替尼布 | 1903008-80-9 |
| Thalidomide 4'-ether-alkylC2-amine hydrochloride | Thalidomide-linker 6 | 2341840-99-9 |
| Thalidomide-NH-PEG3-propionic acid | Pomalidomide-PEG3-CO2H | 2138440-82-9 |
| HLM006474 | CS-1224 | 353519-63-8 |
| PD168393 | 194423-15-9 | |
| (S,R,S)-AHPC-phenol-C4-NH2 dihydrochloride | (S,R,S)-AHPC-PHENOL-C4-NH2 (DIHYDROCHLORIDE) | 2376990-26-8 |
| Lapatinib ditosylate monohydrate | 二对甲苯磺酸拉帕替尼一水合物 | 388082-78-8 |
| (E/Z)-AG490 | 酪氨酸磷酸化抑制剂AG490 | 134036-52-5 |
| Almonertinib mesylate | 阿美替尼甲磺酸盐 | 2134096-06-1 |
| Antiviral agent 24 | N6-(3-Trifluoromethylbenzyl)adenosine | 23661-03-2 |
| 123C4 | 化合物123C4 | 2034159-30-1 |
| MB05032 | 2-氨基-5-异丁基-4-[5-膦酰基-2-呋喃基]噻唑 | 261365-11-1 |
| Linagliptin | 利拉利汀 | 668270-12-0 |
| FIN56 | 1083162-61-1 | |
| iFSP1 | 1-amino-3-(4-methylphenyl)pyrido[1,2-a]benzimidazole-2,4-dicarbonitrile | 150651-39-1 |
| GPX4-IN-3 | 化合物 GPX4-IN-3 | 2761004-85-5 |
| Pifithrin-β hydrobromide | 环状抑制剂-Α氢溴酸盐 | 511296-88-1 |
| NADPH tetrasodium salt | 还原型辅酶Ⅱ四钠 | 2646-71-1 |
| Eugenol-d3 | 1335401-17-6 | |
| Alogliptin-d3 | 1133421-35-8 | |
| Setanaxib | 2-(2-氯苯基)-4-[3-(二甲基氨基)苯基]-5-甲基-1H-吡唑并[4,3-C]吡啶-3,6(2H,5H)-二酮 | 1218942-37-0 |
| OSI-420 free base | 2-[[4-[(3-乙炔基苯基)氨基]-7-(2-甲氧基乙氧基)-6-喹唑啉基]氧基]乙醇 | 183321-86-0 |
| AZD3759 | 1626387-80-1 | |
| RG 13022 | RG-13022 | 136831-48-6 |
| Compound 56 | N-(3-溴苯基)-6,7-二乙氧基-4-喹唑啉胺 | 171745-13-4 |
| Pleconaril | 普可那利 | 153168-05-9 |
| Erastin2 | 4(3H)-Quinazolinone, 2-[[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]methyl]-3-[4-(1-methylethoxy)[1,1'-biphenyl]-3-yl]- | 1695533-44-8 |
| AR-9281 | 1-[(1-Acetylpiperidin-4-yl)-3-adamantan-1-yl]urea | 913548-29-5 |
| AP-III-a4 | 1177827-73-4 | |
| Golgicide A-2 | 1394285-50-7 | |
| Rupintrivir | (2E,4S)-4-[(2R,5S)-2-(4-氟苄基)-6-甲基-5-(5-甲基异恶唑-3-基甲酰氨基)-4-氧代庚酰氨基]-5-[[(3S)-2-氧代-3-吡咯烷基]-2-戊烯酸乙酯 | 223537-30-2 |
| Pirodavir | 吡罗达韦 | 124436-59-5 |
| UAMC-3203 hydrochloride | 2271358-65-5 | |
| Pioglitazone-d4 | 匹格列酮-D4 | 1134163-29-3 |
| Deferasirox | 地拉罗司 | 201530-41-8 |
| ONO-AE3-208 | 4-氰基-2-[[2-(4-氟-1-萘基)-1-氧代丙基]氨基]苯基丁酸 | 402473-54-5 |
| Pioglitazone | 匹格列酮 | 111025-46-8 |
| Dopamine-d5 (hydrochloride) | 盐酸多巴胺:(2 - (3 4-DIHYDROXYPHENYL) | 2193106-55-5 |
| Ifebemtinib | Ifebemtinib (BI-853520) | 1227948-82-4 |
| BI-4464 | BI 4464) | 1227948-02-8 |
| GSK215 | 2743427-26-9 | |
| PND-1186 | PND1186 | 1061353-68-1 |
| sEH inhibitor-7 | 化合物 SEH INHIBITOR-7 | 340221-20-7 |
| GSK2256294A | SEH抑制剂(GSK2256294A) | 1142090-23-0 |
| JWG-071 | 2250323-50-1 | |
| BAY885 | BAY-885 | 2307249-33-6 |
| FAPI-46 | 2374782-04-2 | |
| FAPI-34 | 2374782-07-5 | |
| FAP-2286 | FAP2286 | 2581741-18-4 |
| KO-947 | 1695533-89-1 | |
| FR 180204 | FR180204 | 865362-74-9 |
| ASTX029 | ASTX-029 | 2095719-92-7 |
| Anti-inflammatory agent 35 | 化合物T64358 | 2293951-00-3 |
| RLX-33 | 2784577-71-3 | |
| Ravoxertinib | GDC-0994 | 1453848-26-4 |
| Ulixertinib (hydrochloride) | BVD-523 盐酸盐 | 1956366-10-1 |
| DY131 | N'-(4-(二乙氨基)亚苄基)-4-羟基苯甲酰肼 | 95167-41-2 |
| URB597 | 546141-08-6 | |
| BMS-962212 | 1430114-34-3 | |
| Edoxaban tosylate | 伊多塞班对甲苯磺酸盐 | 480449-71-6 |
| Ozagrel | 奥扎格雷 | 82571-53-7 |
| ERK1/2 inhibitor 1 | 2095719-90-5 | |
| Darexaban | N-[2-羟基-6-(4-甲氧基苯甲酰氨基)苯基]-4-(4-甲基-1,4-二氮杂庚烷-1-基)苯甲酰胺 | 365462-23-3 |
| (rel)-AR234960 | 1408311-94-3 | |
| Lidocaine | 利多卡因 | 137-58-6 |
| BI-3663 | 2341740-84-7 | |
| Defactinib | 地法替尼 | 1073154-85-4 |
| BIX02188 | (3Z)-3-[[[3-[(二甲基氨基)甲基]苯基]氨基]苯亚甲基]-2,3-二氢-2-氧代-1H-吲哚-6-甲酰胺 | 334949-59-6 |
| XMD17-109 | XMD17 109 | 1435488-37-1 |
| Asundexian | 2064121-65-7 | |
| GSK2256098 | GSK-2256098 | 1224887-10-8 |
| Conteltinib | 1384860-29-0 | |
| Tizaterkib | CS-2696 | 2097416-76-5 |
| LM22B-10 | 2-[[4-[[4-[BIS-(2-HYDROXYETHYL)-AMINO]-PHENYL]-(4-CHLORO-PHENYL)-METHYL]-PHENYL]-(2-HYDROXY-ETHYL)-AMINO]-ETHANOL | 342777-54-2 |
联系方式
